Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IPH5201 · 1 trial · 1 indication
Number of patients with pathological Complete Response (pCR)
Number of patients with adverse events (AEs) and serious adverse events (SAEs).
| Arm | Type | Description |
|---|---|---|
| IPH5201 + durvalumab + standard chemotherapy | EXPERIMENTAL | Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy. In Cohort 1 only, following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab. |
| Name | Type | Description |
|---|---|---|
| IPH5201 + durvalumab + standard chemotherapy | DRUG | Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy. In Cohort 1 only, Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab. |
Inclusion criteria Patients are eligible to be included in the study only if all of the following criteria apply: 1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol. 2. Provis...
Top 20 of 90 competitors
IPH5201 is an investigational immunotherapy being studied in resectable non-small cell lung cancer. It is given in combination with durvalumab and standard chemotherapy in patients whose tumors are biomarker selected. The Phase 2 MATISSE trial is evaluating this combination in adults with resectable disease across the United States, France, Greece, Hungary, and Poland.
IPH5201 targets CD39, an enzyme involved in the adenosine pathway within the tumor microenvironment. By targeting CD39, the drug is designed to act on immunosuppressive adenosine signaling. It is being developed as a small molecule and is studied in combination with durvalumab, a checkpoint inhibitor, plus standard chemotherapy in non-small cell lung cancer.
IPH5201 is being developed by Innate Pharma S.A., a biopharmaceutical company whose ticker is IPHA. The company is running the Phase 2 MATISSE trial of IPH5201 in combination with durvalumab and standard chemotherapy in patients with resectable non-small cell lung cancer.
IPH5201 is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. The ongoing Phase 2 MATISSE study is recruiting participants and is designed to enroll approximately 70 patients with resectable non-small cell lung cancer.
IPH5201 is being studied in the Phase 2 MATISSE trial, registered as NCT05742607, titled IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer. The trial is currently recruiting, with an estimated enrollment of 70 participants, and it is an uncontrolled, non-randomized study.